Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly completes offer for ImClone

This article was originally published in Scrip

Executive Summary

Lillyhas completed its tender offer for all of ImClone Systems's outstanding shares.. The $70 per share cash offer, conducted through Lilly's subsidiary Alaska Acquisition, expired at midnight EST on November 20th. Around 85.4 million shares were tendered, representing 95.5% of ImClone's issued and outstanding shares. Lilly plans to complete the acquisition through a short-form merger on or by Monday. All outstanding shares of ImClone's common stock not already purchased by Alaska will be converted into the right to receive $70 per share in cash. The offer's completion marks the end of one of this year's most headline-grabbing takeover stories after Bristol-Myers Squibbfailed to acquire ImClone. Lilly subsequently emerged as a mystery bidder and succeeded in offering what chairman Carl Icahn believed was an acceptable bid (Scrip Online, October 7th, 2008).

You may also be interested in...



Myotec and Hybrid merge to form PsiOxus

Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.

Trophos's MitoCare programme receives €6 million EU funding

A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.

Novartis and Alcon reach compromise to settle merger saga

Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC031703

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel